FDA Grants Abemaciclib Breakthrough Status for Refractory Breast Cancer

The FDA has granted the CDK4/6 inhibitor abemaciclib a breakthrough therapy designation as monotherapy for heavily pretreated patients with refractory hormone-receptor-positive advanced breast cancer. http://www.onclive.com/web-exclusives/fda-grants-abemaciclib-breakthrough-status-for-refractory-breast-cancer

http://pharminent.com/2015/10/08/fda-grants-abemaciclib-breakthrough-status-for-refractory-breast-cancer/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s